ArticleJHLT open2026
Invasive aspergillosis in lung and heart transplant recipients.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in lung transplant (LT) and heart transplant (HT) recipients. Most of the risk is in the first year post-transplant. In this review, the epidemiology, diagnosis and treatment of IA are examined in detail. The challenges in diagnosis are highlighted. Whilst culture and histology are the cornerstone, the emerging role of serological and molecular methods is discussed. Treatment is a multipronged approach with drug-drug interactions and toxicity impacting outcomes. New antifungals are in development and have the potential to improve efficacy and reduce toxicity. Ongoing research is required to fully delineate the risk factors for IA, determine the optimal prevention strategy and develop new diagnostic tools and treatments so that outcomes from IA in LT and HT recipients continue to improve.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.